event tracking

International Linked Clinical Trials (iLCT)

26 results.

March 13, 2023 Van Andel Institute, Cure Parkinson’s renew $4.5 million co-funding agreement to support collaborative Parkinson’s clinical trials program

Grand Rapids, Mich. (March 13, 2023) — Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce that their co-funding agreement, which supports…

January 10, 2023 Cough medicine offers hope of new treatment to slow the progression of Parkinson’s disease

London, United Kingdom (Jan. 10, 2023) — Following promising results reported at Phase 2 in 2020, a large-scale Phase 3 clinical trial of ambroxol,…

April 5, 2022 Top-line results reported from clinical trial of diabetes drug in Parkinson’s

This release has been republished from Cure Parkinson’s.

Researchers from Cedars Sinai Hospital, Los Angeles, have presented their initial top line results of…

December 13, 2021 A year — and a quarter century — in review

As 2021 comes to a close, so too does Van Andel Institute’s celebration of our 25th anniversary. The Institute’s story began with a vision: to…

March 18, 2021 New uses for existing medications provide hope for Parkinson’s disease breakthroughs

Drug repurposing program seeks to find treatments that slow or stop Parkinson’s progression and serve as a roadmap for similar initiatives in other…

September 20, 2020 International Linked Clinical Trials strategic funding for Parkinson's now worth US$6.75 million

LONDON (Sept. 21, 2020) — The Cure Parkinson’s Trust (CPT) and Van Andel Institute (VAI) are delighted to welcome a third strategic funding partner, The…

February 12, 2020 $4.5 million co-funding agreement for Parkinson’s research announced

LONDON (Feb. 13, 2020) — The Cure Parkinson’s Trust (CPT) and Van Andel Institute (VAI) are delighted to announce a new three-year co-funding agreement that…

January 12, 2020 Phase II clinical trial of respiratory drug for treatment of Parkinson's disease reveals promising results

The Cure Parkinson's Trust (CPT) is delighted to announce the publication of the results of a Phase II clinical trial evaluating ambroxol as a…